Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.
1. A pharmaceutical composition comprising: micronized progesterone, soy bean lecithin, and olive oil, wherein at least about 80% of the particles of said micronized progesterone are characterized by a particle size of between 1 and 15 μm, as measured in the composition.
2. The pharmaceutical composition according to claim 1 , wherein the progesterone/oil ratio is between 0.15/1 and 3/1.
3. The pharmaceutical composition according to claim 1 , wherein the soy bean lecithin/oil ratio is between 0.005/1 and 0.3/1.
4. The pharmaceutical composition according to claim 1 , further comprising an oestrogen or an ester-type derivative thereof.
5. The pharmaceutical composition according to claim 1 , wherein at least the progesterone is in suspension in the oil.
6. The pharmaceutical composition according to claim 1 , in the form of a soft capsule.
7. The pharmaceutical composition according to claim 1 , in unit dosage form comprising between 2 mg and 600 mg of micronized progesterone.
8. A method for preparing a pharmaceutical composition comprising the following successive steps:
mixing olive oil with soy bean lecithin in order to obtain a mixture; and
adding micronized progesterone to said mixture to obtain a homogeneous suspension, wherein at least about 80% of the particles of said micronized progesterone are characterized by a particle size of between 1 and 15 μm, as measured in the composition.
9. A method for the treatment of a physiological condition linked to insufficiency of progesterone secretion comprising the step of administering to the patient a pharmaceutical composition comprising: micronized progesterone, soy bean lecithin, and olive oil, wherein at least about 80% of the particles of said micronized progesterone are characterized by a particle size of between 1 and 15 μm, as measured in the composition.
10. The method according to claim 9 , in which the pharmaceutical composition further contains an oestrogen, or an ester-type derivative thereof.
11. The pharmaceutical composition according to claim 1 , wherein the progesterone/oil ratio is between 0.25/1 and 2/1.
12. The pharmaceutical composition according to claim 1 , wherein the progesterone/oil ratio is between 0.40/1 and 1/1.
13. The pharmaceutical composition according to claim 1 , wherein the progesterone/oil ratio is 0.67/1.
14. The pharmaceutical composition according to claim 1 , wherein the soy bean lecithin/oil ratio is between 0.01/1 and 0.2/1.
15. The pharmaceutical composition according to claim 1 , wherein the soy bean lecithin/oil ratio is between 0.040/1 and 0.1/1.
16. The pharmaceutical composition according to claim 1 , wherein the soy bean lecithin/oil ratio is 0.0067/1.
17. The pharmaceutical composition according to claim 4 , wherein the oestrogen, or the ester-type derivative thereof is selected from the group consisting of 17-beta-oestradiol, oestrone, 17-alpha-ethinyl oestradiol and oestradiol valerianate, or phyto-oestrogens.
18. The pharmaceutical composition according to claim 4 , wherein the oestrogen, or the ester-type derivative thereof is 17-beta-oestradiol.
19. The pharmaceutical composition according to claim 7 , comprising between 30 mg and 300 mg of micronized progesterone.
20. The pharmaceutical composition according to claim 7 , comprising between 100 mg and 200 mg of micronized progesterone.
21. The pharmaceutical composition according to claim 1 , wherein at least 50% of the particles of said micronized progesterone have a particle size of between 1 and 10 μm, as measured in the composition.
22. The pharmaceutical composition according to claim 1 , wherein at least 25% of the particles of said micronized progesterone have a particle size of between 1 and 5 μm, as measured in the composition.
23. The method according to claim 10 , wherein the oestrogen, or the ester-type derivative thereof is selected from the group consisting of 17-beta-oestradiol, oestrone, 17-alpha-ethinyl oestradiol and oestradiol valerianate, or phyto-oestrogens.
24. The method according to claim 10 , wherein the oestrogen, or the ester-type derivative thereof is 17-beta-oestradiol.
25. The method according to claim 9 , wherein at least 50% of the particles of said micronized progesterone have a particle size of between 1 and 10 μm, as measured in the composition.
26. The method according to claim 9 , wherein at least 25% of the particles of said micronized progesterone have a particle size of between 1 and 5 μm, as measured in the composition.